chartexchange

IBRX261120P00007000
IBRX Nov 20 2026 7.00 Put
optionOPRA

EODOct 16, 2026
0.25USD1,067Vol4,059OI
Loading…
Underlying
Underlying Price
$8.28
Type
Put
Strike
7
Expiration
Nov 20, 2026
DTE
31d
Moneyness
OTM
Intrinsic
$0.00
IBRX 7 Put Across Expirations
ExpirationDTELastChangeVolOpen Int
Oct 23, 20263d$0.05+0.00%101,102
Oct 30, 202610d$0.05-50.00%178
Nov 6, 202617d$0.11+0.00%1111
Nov 13, 202624d$0.20-60.00%8001,105
Nov 20, 202631d$0.25+66.67%1,0674,059
Nov 27, 202638d——00
Dec 18, 202659d——0106
Mar 19, 2027150d$0.95-9.52%5440
Apr 16, 2027178d$1.37-9.87%12
May 21, 2027213d$1.25-53.87%111
Aug 20, 2027304d$2.00-28.06%34
Nov 19, 2027395d$2.25+28.57%521,751
Mar 17, 2028514d$2.30+12.20%291
Jan 19, 2029822d$2.50-3.85%543
IBRX Nearby Strikes · Nov 20, 2026
StrikeLastChangeVolOpen IntMoneyness
1 P$0.10-62.96%17OTM
2 P$0.10-50.00%32OTM
3 P——00OTM
4 P$0.03-40.00%16OTM
5 P$0.10+0.00%1256OTM
6 P$0.10-23.08%2503,143OTM
7 P$0.25+66.67%1,0674,059OTM
8 P$0.55+30.95%2642,195OTM
9 P$0.90+21.62%651,572ITM
10 P$1.48+28.70%99741ITM
11 P$2.20+41.03%7394ITM
12 P$2.20-26.67%2074ITM
13 P$3.60+16.88%23ITM
IBRX Profile

immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.